Midazolam Kalceks (Midazolam)

Midazolam binds to a specific site on the GABA‑A receptor complex, enhancing the natural inhibitory action of GABA. This increases chloride ion flow into neurons, hyperpolarizing the cell membrane and decreasing neuronal excitability, which results in sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

Dosing of Midazolam Kalceks is individualized. The prescribing clinician determines the appropriate dose, route, and frequency based on the patient’s age, weight, clinical indication, and response. Exact regimens are not provided here and should follow the prescriber’s order and local guidelines.

Midazolam is classified as Pregnancy Category D, indicating evidence of fetal risk. It should only be used during pregnancy when the potential benefit justifies the risk. The drug is excreted in breast milk; therefore, breastfeeding is generally not recommended while receiving Midazolam unless the benefit to the mother outweighs potential infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable), and necessary import documentation.

Compared with other benzodiazepines, Midazolam has a rapid onset and relatively short duration of action, making it suitable for brief procedures. Unlike longer‑acting agents such as diazepam, Midazolam allows quicker recovery. However, all benzodiazepines share risks of respiratory depression and dependence, so selection depends on procedural length, patient factors, and desired recovery profile.

Midazolam Kalceks should be stored at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect from moisture and direct light, and ensure the container is tightly sealed to maintain sterility until use.

The product is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or rectally, depending on the clinical need. Administration should be performed by qualified healthcare professionals using aseptic technique, with dosage and rate adjusted to the patient’s response and monitoring requirements.

The most critical risks include respiratory depression, especially when combined with other CNS depressants, severe hypotension, paradoxical reactions such as agitation, and rare allergic reactions like anaphylaxis. Continuous monitoring of breathing, blood pressure, and level of consciousness is essential during and after administration.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, those with severe respiratory insufficiency, acute narrow‑angle glaucoma, and individuals who have taken large amounts of alcohol or other CNS depressants shortly before administration. Caution is also advised in patients with myasthenia gravis or severe hepatic impairment.